ethyl-{5-[3-formyl-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-carbamic acid tert-butyl ester | 837364-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: ethyl-{5-[3-formyl-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-ethyl-N-[[5-[3-formyl-1-(oxan-2-yl)indazol-5-yl]-4-methylpyridin-3-yl]methyl]carbamate
• CAS: 837364-61-1
• 化学式: C₂₇H₃₄N₄O₄
• 分子量: 478.591
• InChiKey: GGPRFMDSWJSQJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  86.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl-{5-[3-formyl-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-carbamic acid tert-butyl ester 在 盐酸羟胺 、 三乙胺 、 三氯乙酰氯 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以92%的产率得到{5-[3-Cyano-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-carbamic acid tert-butyl ester
  参考文献：
  名称：

  3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

  摘要：

  描述了在3-位置带有取代氮的5-成员杂环的3,5-二取代吲唑化合物，这些化合物调节和/或抑制细胞增殖，如蛋白激酶活性。这些化合物和含有它们的药物组合物能够调节和/或抑制介导CDK依赖性疾病的不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。

  公开号：

  US20050090529A1
• 作为产物：
  描述：

  tert-butyl ((5-bromo-4-methylpyridin-3-yl)methyl)(ethyl)carbamate 、 5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium acetate 、 联硼酸频那醇酯 、 potassium phosphate 作用下， 以 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 6.5h， 以44%的产率得到ethyl-{5-[3-formyl-1-(tetrahydro-pyran-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING A CDK INHIBITOR
  [FR] COMPOSITIONS PHARMACEUTIQUES CONTENANT UN INHIBITEUR DES CDK

  摘要：

  本发明涉及含有{5-[3-(4,6-二氟-1 H-苯并咪唑-2-基)-1 H-吲唑-5-基]-4-甲基吡啶-3-基甲基}-乙基胺的药物和冻干组合物，该物质是细胞周期依赖性激酶（CDKs）的抑制剂。这些药物和冻干组合物适用于肌肉注射，其中组合物包括{5-[3-(4,6-二氟-1 H-苯并咪唑-2-基)-1 H-吲唑-5-基]-4-甲基吡啶-3-基甲基}-乙基胺、一种增溶剂和一种稳定剂，如本文所定义。还公开了制备这些组合物的方法，以及通过给药这些组合物来治疗细胞增殖性疾病的方法。

  公开号：

  WO2006024945A1

文献信息

• [EN] 3,5 DISUBSTITUTED INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MEDIATING OR INHIBITING CELL PROLIFERATION<br/>[FR] COMPOSES D'INDAZOLE 3,5 DISUBSTITUTES, COMPOSITIONS PHARMACEUTIQUES, ET PROCEDES POUR MEDIER OU INHIBER LA PROLIFERATION CELLULAIRE
  申请人：PFIZER

  公开号：WO2005009997A1

  公开（公告）日：2005-02-03

  3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了能够调节和/或抑制细胞增殖的3,5-二取代吲唑化合物，例如蛋白激酶的活性。这些化合物和含有它们的药物组合物能够通过调节和/或抑制不需要的细胞增殖来调解CDK依赖性疾病。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病性视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣等。
• INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Hood John

  公开号：US20110034441A1

  公开（公告）日：2011-02-10

  Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.

  本文描述了一种治疗与异常Wnt信号传导有关的疾病或紊乱的方法，使用各种化合物，包括Wnt抑制剂化合物。更具体地，涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（如癌症、异常细胞增殖、血管生成、阿尔茨海默病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt信号传导组分突变引起的遗传疾病。
• Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
  申请人：Ma Chunrong

  公开号：US20060116519A1

  公开（公告）日：2006-06-01

  The present invention relates to novel synthetic methods for the preparation of intermediates of 35-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]4-methyl-pyridin-3-yl methyl}-ethyl-amine.

  本发明涉及一种新型合成方法，用于制备3 5-[3-(4,6-二氟-1H-苯并咪唑-2-基)-1H-吲唑-5-基]4-甲基-吡啶-3-基甲基}-乙基胺的中间体。
• 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
  申请人：Kephart Elizabeth Susan

  公开号：US20060142345A1

  公开（公告）日：2006-06-29

  3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制细胞增殖，如蛋白激酶活性的3,5-双取代吲唑化合物。这些化合物和含有它们的药物组合物能够调节CDK依赖性疾病，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
  申请人：Kephart Elizabeth Susan

  公开号：US20050026960A1

  公开（公告）日：2005-02-03

  3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了3,5-二取代吲唑化合物，其调节和/或抑制细胞增殖，如蛋白激酶的活性。这些化合物和含有它们的药物组合物能够介导CDK依赖性疾病，以调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予有效剂量的这些化合物的方法来治疗癌症以及与不必要的血管生成和/或细胞增殖相关的其他疾病状态，例如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。